Accessibility Menu
Genelux logo

Genelux(NASDAQ) GNLX

Market Cap$131.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-52%
5 YearN/A
1 Year-13%
1 Month+1%
$2.95
+0.17%
+0.00Today
After hours$2.98+$0.03 (+1.19%)
Genelux last closing stock price
MetricPriceDate
Last closeUSD 2.942026-07-31
Genelux stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.73%USD 2.892026-07-24
1 month+1.38%USD 2.902026-07-01
3 month+7.3%USD 2.742026-05-01
Year to date-32.57%USD 4.362025-12-31
1 year-13.27%USD 3.392025-07-31
3 year-85.66%USD 20.502023-08-01
Since inception-52.2%USD 6.152023-01-26

Genelux Financials at a Glance

Market Cap

$131.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.00K

Net Income (TTM)

-$31.78M

EPS (TTM)

-$0.85

P/E Ratio

-3.44

Dividend

$0.00

Beta (Volatility)

1.47 (Average)

Price

$2.95

Volume

219,561

Open

$2.97

Previous Close

$2.98

Daily Range

$2.91 - $2.99

52-Week Range

$2.29 - $8.54

Estimated Earnings Date

Aug 6, 2026

GNLX News

scientist viewing bacteria test gloves petri dish

Why Shares of Genelux Climbed This Week

James HalleyJul 28, 2023
person in waiting room looking to side

Why Shares of Genelux Corporation Jumped This Week

James HalleyJun 1, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genelux

Genelux develops virus-based therapies for hard-to-treat cancers. Its main products aim to help patients with aggressive tumors. These therapies use modified viruses to target and destroy cancer cells.

Lab Bench to Bedside: What Genelux Sells

  • Olvi-Vec (Lead Therapy): Modified virus therapy for ovarian and lung cancer; 100% of 2025 revenue from licensing, not product sales.
  • V2ACT Immunotherapy: Early-stage therapy for pancreatic cancer; no commercial revenue yet.
  • V-VET1: Experimental treatment for blood and solid cancers; not yet generating revenue.
  • Licensing Agreements: Revenue from licensing technology to partners; all 2025 revenue from this source.
  • Clinical Manufacturing: In-house facility produces materials for trials; no direct sales revenue.

Growth Spurts and Strategic Moves

  • Signed exclusive licensing deal with Newsoara for China, Taiwan, Hong Kong, and Macau in 2021.
  • Launched Phase 3 trial for Olvi-Vec in ovarian cancer in 2022.
  • Started Phase 2 trial for lung cancer in the U.S. in October 2024.
  • Expanded San Diego manufacturing and lab facilities in 2025.
  • Raised capital through equity offerings in 2024, 2025, and January 2026.

Genelux’s Secret Sauce

Genelux owns a proprietary platform to rapidly develop virus-based cancer therapies. Its in-house manufacturing gives it control over clinical supply. Strategic partnerships help it access international markets and share development costs.

Five Things You Need to Know

  • No product sales; all 2025 revenue from licensing agreements.
  • Net loss was $32.1 million in 2025, up 7% from 2024.
  • Cash and investments totaled $14.6 million at end of 2025.
  • Ongoing operating losses raise concerns about future funding needs.
  • All therapies are still in clinical trials, not yet approved for sale.

Bottom Line

Genelux focuses on developing virus-based cancer therapies and relies on licensing for revenue. The company faces ongoing losses and must secure more funding to continue its research.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

26

CEO

Thomas D. Zindrick

Website

www.genelux.com

Headquarters

Westlake Village, CA 91361, US

GNLX Financials

Key Financial Metrics (TTM)

Gross Margin

-3550.00%

Operating Margin

-422037.50%

Net Income Margin

-397225.00%

Return on Equity

-165.18%

Return on Capital

-251.07%

Return on Assets

-98.17%

Earnings Yield

-29.07%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$131.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

44.84M

Volume

219.56K

Avg. Volume

174.75K

Financials (TTM)

Gross Profit

-$284.00K

Operating Income

-$33.76M

EBITDA

-$32.04M

Operating Cash Flow

-$25.89M

Capital Expenditure

-$1.99M

Free Cash Flow

-$27.88M

Cash & ST Invst.

$26.21M

Total Debt

$2.50M

Genelux Performance Analysis

Genelux annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 11,068,000N/A
20232023-12-31USD 170,000-98.5%
20242024-12-31USD 8,000-95.3%
20252025-12-31USD 8,0000.0%
Genelux sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
Genelux annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.21-69.4%
20232023-12-31USD -1.16446.1%
20242024-12-31USD -0.95-18.0%
20252025-12-31USD -0.86-9.0%
Genelux sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.8%
Q32025-09-30-5.0%
Q42025-12-31-19.0%
Q12026-03-3112.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$1.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$131.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.07M

N/A

Employees

26

N/A

Net Income

-$7.13M

+4.9%

EBITDA

-$7.08M

+3.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$26.21M

-25.3%

Total Debt

$2.50M

+39.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.18M

+50.3%

Short Term Debt

$316.00K

-6.2%

Return on Assets

-98.17%

N/A

Return on Invested Capital

-1.35%

N/A

Free Cash Flow

-$6.98M

-27.7%

Operating Cash Flow

-$6.06M

-11.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALDXAldeyra The
$1.53-0.65%
MREOMereo BioPharma Group plc
$0.32-7.94%
ACIUAC Immune S.A.
$2.22+1.37%
CLLSCellectis S.A.
$2.75+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About GNLX

What is the current price of Genelux?

Genelux is trading at $2.98 per share.

What is the 52-week range for Genelux?

Over the past 52 weeks, Genelux has traded between $2.29 and $8.54.

How much debt does Genelux have?

As of the most recent reporting period, Genelux reported total debt of $2.50M.

How much cash does Genelux have on hand?

Genelux reported $9.27M in cash and cash equivalents in its most recent financial results.

What is Genelux’s dividend yield?

Genelux does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services